ONTX – Looking For The Reversal Pattern

Onconova Therapeutics, Inc. (ONTX) -Nasdaq   Onconova has recently plunged about $19 from the 52-week high at $31.13, reached just a month ago to the current level in mid-$13s and reaching the.

November 11- EOD

I am gone for a little while and the market goes crazy, bounces, and then we have today which has both sell offs and rallies. To be honest, it is.

Quick take on Geron’s Imetelstat abstract

Today we finally got a glimpse at the ongoing investigator sponsored study of Geron (GERN) imetelstat in myelofibrosis. We have previously discussed this program here. The abstract can be found.

TSRO – A look at Tesaro

Following additional information released at ASCO 2013 and their recent quarterly updated, we wanted to take a moment to talk about Tesaro (TSRO). Since their IPO, Tesaro’s stock is up.

Horizon Pharma continues cash burn and dilution

We last wrote on Horizon Pharma (NASDAQ: HZNP) following their FDA approval of RAYOS, but seems not much has changed. However, the stock has risen roughly 60% year to date.

ASH 2013 Preview on ALL/CML/MDS/AML

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. The first series in our preview covered what to expect in.

ASH 2013 Preview on Myelofibrosis

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs.

Week’s Option Activity (10/31~11/4)

The following stocks had notable activity in their options during the past week(s): $VNDA (10/31): Lots of activity – we will stick to the bigger trades. 1,000 NOV 4.0 strike.

ASH 2013 Preview on Lymphoid Malignancies

This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking.

November 5- EOD

The morning looked bad but the sector came back a little. There was some sporadic buying of oncology names but nothing major. It will be very interesting to see how.

ASH 2013 Preview on rare blood disorders

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. Orphan diseases has been a key element in the bull market.

November 4- EOD

(This was from yesterday. Due to the server issues, I am not sure many of you saw it, so I am reposting.) I take one day to not write an.

ASH 2013 Preview on Multiple Myeloma

This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs.

CLDX – A look at CDX-1127

Celldex Therapeutics (CLDX) has one of the most anticipated data releases amongst small biotech companies this fall. They are scheduled to present data from their Phase 1 dose-escalation trial of.

October 31- EOD

ARIA is doing its best to single handedly crush biotech sentiment and grind it into a bloody pulp. As I have said before, if this is the bursting of a.

Catalyst Watch – Vol. 1, Edition 6 (10/30/13)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are.

October 30- EOD

The sector seems almost perilously balanced between putting in a solid base for the next leg higher and setting up for another leg lower. The freefall that we have seen.

October 29- EOD

Well, it seemed like an odd day for the sector in that it was almost directionless. This is not to say that there were not moves among individual stocks but.

Ariad- Where Do They Go From Here

Following the FDA’s clinical hold, then discontinuation of the Phase III trial in front line CML for Ariad’s only marketed drug, Iclusig, the most pressing issue comes down to are.

October 28- Mid day

I have not followed the biotech market very close the end of last week but it seems like more of the same. There is a number of issues that I.

Browsing 20 / 3 articles